Core Laboratories Inc. /DE/ (CLB) · Oct 28, 2026 · Earnings
Miss — GAAP EPS $0.12 vs ~$0.16 consensus
Core Lab earnings showed recovering international demand and a slight revenue beat, but Q3 EPS missed consensus and Q4 guidance is broadly flat.
Core Lab is an oilfield-services specialist built around reservoir characterization and production-enhancement technologies, with the growth thesis increasingly tied to international and offshore activity while U.S. land activity remains more cyclical. Current published estimates called for roughly $131.9 million of revenue and $0.16 of EPS, making the quarter a revenue near-miss-to-beat but an earnings miss.
The top line recovered, but not enough to change the broader earnings trend. Q3 revenue rose 6.0% sequentially to $132.1 million and was down 1.8% year over year, modestly above the published consensus near $131.9 million. Reservoir Description led the rebound, up 7.1% sequentially, while Production Enhancement rose 4.1%. The mix supports the company’s international-recovery narrative, but nine-month revenue was still down 2.5% and operating income was down 43.1% year over year. (Statements of Operations; Segment Information)
| Metric | Q3 2026 | Q2 2026 | Q3 2025 | Versus expectation |
|---|---|---|---|---|
| Revenue | $132.1M (Statements of Operations) | $124.6M | $134.5M | Slightly above ~$131.9M consensus |
| GAAP EPS | $0.12 (Statements of Operations) | $0.12 | $0.31 | Below ~$0.16 consensus |
| Ex-items EPS | $0.16 (Non-GAAP reconciliation) | $0.11 | $0.22 | Roughly in line with adjusted expectation |
| Operating income | $12.1M (Statements of Operations) | $9.2M | $20.9M | Down 42.3% year over year |
| Free cash flow | $1.7M (Free Cash Flow computation) | — | — | Positive, but modest |
The miss came below revenue, not from a collapse in demand. Ex-items operating income rose 35% sequentially, but remained 24% below the prior year, while GAAP EPS was held down by a 41% effective tax rate and ongoing pressure from geopolitical disruptions. Reservoir Description’s 78% sequential incremental margin was encouraging, but Production Enhancement operating income fell 17.2% sequentially as delayed Gulf of America diagnostic projects offset stronger product sales. (Non-GAAP reconciliation; Segment Information)
The international recovery is real but still fragile. Reservoir Description revenue improved across Europe-Africa, Asia-Pacific, Latin America and the Middle East, and the company cited expanded Middle East analytical work plus an Australian appraisal program. However, Middle East demand remained below pre-conflict levels, and the company said early-Q4 attacks had already delayed regional projects. That makes the recovery story more dependent on a gradual normalization of international activity than on an immediate step-up. (Reservoir Description) 〔0〕
Q4 guidance keeps the recovery measured rather than accelerating. Revenue is projected at $128.5 million to $134.5 million, implying a roughly flat sequential quarter around the midpoint, with EPS of $0.12 to $0.20. The range is consistent with the company’s prior Q3 revenue and EPS framework, so the new information is mainly the confirmation that geopolitical delays and normal U.S. year-end seasonality are still limiting near-term growth. (Industry and Core Lab Outlook and Guidance) 〔1〕
Cash generation and capital allocation remain secondary positives, not enough to offset the earnings miss. The company generated $1.7 million of Q3 free cash flow, repurchased 87,873 shares for approximately $1.1 million, reduced net debt to $93.4 million, and maintained its $0.01 quarterly dividend. Those actions show balance-sheet control, but cash generation was modest relative to the company’s stated focus on free cash flow. (Liquidity, Free Cash Flow, Share Repurchases, and Dividend)
Bottom line: Core Lab’s operating story improved sequentially, especially internationally, but the quarter still missed the market’s EPS bar and Q4 points to stabilization rather than a breakout. The business is recovering, but the recovery remains exposed to geopolitical delays, elevated taxes and uneven margins.
Q3 earnings call, October 29, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!